A subsidiary of PICC Property and Casualty in Taizhou Medical High-Tech Zone has issued the country's first "Pharma R&D Insurance" policy.

Results from the violin blind evaluation at the 2026 Shanghai Spring International String Music Culture Week have been announced, with a Chinese-made instrument taking the top honor.

Ab&B Bio-Tech, a Taizhou-based listed biopharmaceutical company, has signed an exclusive agreement for overseas expansion with Walvax Hong Kong, a wholly owned subsidiary of the leading Chinese vaccine producer Walvax.

Ten enterprises from Taizhou have been newly certified under the 2025 "Jiangsu Premium" program, marking a new milestone in local brand development.

Taizhou's innovation-driven manufacturing sector continues to rise.

Taizhou has been actively working to improve its business environment in recent years, creating favorable conditions for enterprises to grow and succeed.

Taizhou's foreign trade showed notable improvement in August, with total imports and exports reaching $2.21 billion, up 16.4 percent year-on-year and ranking second in the province.

A joint supervision mechanism for special goods entering and leaving the country was recently implemented in the Taizhou Medical High-tech Zone.